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Summary In photodynamic therapy (PDT), photosensitisers accumulate somewhat preferentially in malignant
tissues; photoactivation with appropriate wavelength of light releases toxic molecular species which lead to
tumour tissue death. In order to target ovarian cancer with increased specificity, a chlorin-based photosensitiser
(chlorin e6 monoethylendiamine monoamide) was conjugated to OC125, a monoclonal antibody recognising an
antigen expressed in 80% of non-mucinous ovarian cancers. In previous work, this immunoconjugate (IC) was
shown to be selectively phototoxic to cancer cells from ovarian cancer patients ex vivo and to localise
preferentially in ovarian cancer tissue in vivo. In this study we report results from in vivo phototoxicology and
photodynamic treatment studies using this IC in a murine model for ovarian cancer. A comparison of single vs
multiple treatments was also made. For in vivo experimentation, Balb C nude mice were injected with 30 x 106
NIH:OVCAR 3 cancer cells to create an ascitic tumour model. Animals were then given intraperitoneal
injections of the immunoconjugate (0.5 mg kg-'). Twenty-four hours later the intraperitoneal surfaces were
exposed to 656 nm light from an argon-ion pumped-dye laser (50 mW, 656 nm), using a cylindrical diffusing
tip fibre. The overall treatment was given either once or multiply. No animals died from treatment
complications. Twenty-four hours following one and three PDT treatments, the percentage of viable tumour
cells in the ascites of the treated animals analysed ex vivo was 34% and 5% of control for one and three
treatments respectively. With respect to survival, all control mice (n= 18) died between 30 and 50 days.
However, for those treated three times (n = 10), 40% were still alive after 50 days, and for those treated four
times (n= 12) 58% were alive after 50 days. Evaluation with log-rank test revealed a significant survival with
intraperitoneal PDT compared with controls (P=0.0006). These preliminary results suggest that PDT with an
OC125 immunoconjugate may be an effective therapy for the management of advanced ovarian cancer. Clinical
application of this therapy needs to be further optimised and may require multiple treatments, similar to
fractionated radiation therapy and cyclic chemotherapy, in order to control malignant disease with acceptable
toxicity to normal tissue.
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Ovarian cancer is a disease which is largely confined to the
peritoneal cavity and, therefore, may be amenable to
localised therapies which have tumour cell selectivity.
Photodynamic therapy (PDT) is an experimental approach
to the treatment of neoplasms which may alleviate some of
the problems associated with the lack of specificity of
conventional therapies. PDT involves the use of non-toxic
compounds, photosensitisers, which are preferentially re-
tained in malignant tissues by a variety of mechanisms
(Dougherty, 1987; Hasan and Parrish, 1996). Exposure to
the appropriate wavelength of light activates the photo-
sensitiser to release toxic substances such as singlet oxygen,
which result in phototoxicity and tumour cell death
(Henderson and Dougherty, 1992; Pass, 1993). PDT
provides increased selectivity by combining photosensitiser
localisation to the tumour with spatial control of illuminated
areas. In theory, this should minimise damage to normal
tissue.
Photodynamic treatment of ovarian cancer in experimental
animals was initially described by Tochner et al. (1985, 1986).
Using the photosensitiser, haematoporphyrin derivative
(HPD) and intraperitoneal light, these investigators showed
effective eradication of a syngeneic murine ascites tumour
(embryonal ovarian carcinoma) in 17 of 20 animals with four
treatments of HPD and intraperitoneal exposure to light.
These results prompted phase I trials of PDT using a
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relatively purified form of HPD, Photofrin (PF), for the
treatment of disseminated intraperitoneal malignancies
(Sindelar et al., 1991; Delaney et al., 1993). In this study 18
women with ovarian cancer were treated with PF and PDT;
four of the 18 achieved a complete response. Toxicity in this
trial was primarily related to the non-specific uptake of the
photosensitiser. In addition to prolonged skin phototoxicity
which persists for 30-60 days, small bowel perforations
developed at anastomotic sites. Other investigators have
shown that HPD is not selectively retained in human ovarian
cancers implanted subcutaneously (Peterson et al., 1992).
These problems of non-specific localisation have prompted
the search for new photosensitisers with improved specificity
(Gomer, 1991).
One way to improve target specificity of phototoxic
compounds is to link them with tumour-specific monoclonal
antibodies (Mew et al., 1983; Hasan, 1992). In previous
studies we have reported the conjugation of a chlorin
photosensitiser site specifically to the monoclonal antibody
OC125 (Hasan et al., 1989; Goff et al., 1991). Chlorin
derivatives are efficient photosensitisers with a high yield of
singlet oxygen. OC125 recognises the antigen CA125, which
is expressed by 80% of non-mucinous ovarian cancers (Bast
et al., 1981). The conjugate was significantly more
phototoxic to ovarian cancer cells both in vitro (cell lines)
and ex vivo (from cancer patients), while exhibiting very
little phototoxicity to CA125-negative cells (Goff et al., 1991,
1992). Biodistribution assays of the immunoconjugate in an
ascitic Balb/C nude mouse model injected with human
ovarian cancer were reported previously (Goff et al., 1994).
In this present study we report our experience with
photoimmunotherapy using an OC125 immunoconjugate
and intraperitoneal light in the nude mouse ascitic ovarian
cancer model.Photoimmunotherapy of ovarian cancer
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Material and methods
Tumour cells and antibody
NIH:OVCAR 3 cells were from the American Tissue Culture
Collection (Rockville, MD, USA). This cell line was derived
from the ascites of a patient with ovarian cancer (Hamilton et
al., 1983). The monoclonal antibody OC125 was a generous
gift of Centocor (Malvern, PA, USA). Cells were grown in
RPMI-1640 medium (Gibco, Grand Island, NY, USA)
supplemented with heat-inactivated fetal bovine serum and
kept in an incubator at 37°C in an atmosphere of 5% carbon
dioxide. For tumour transplantation, cells were trypsinised
(Trypsin-EDTA, Gibco), centrifuged at 1000 r.p.m. for
10 min (Model 6000B, Sorval Centrifuges, Dupont, Wilming-
ton, DE, USA), and resuspended in 1 ml of phosphate-
buffered saline (PBS, Gibco) for intraperitoneal injection.
Tumour model
Experiments were carried out in a murine model for ovarian
cancer developed by Hamilton et al. (1984). Balb/C athymic
nude mice (Charles River Breeding Laboratories) were given
intraperitoneal injections of 30 x 106 NIH:OVCAR 3 cells.
This results in the development of serosal metastases similar
to that of ovarian cancer in humans. Disease progression is
characterised by the development of massive ascites and
extensive intraperitoneal tumours. Within several weeks,
animals develop clinical evidence of ascites. Animals which
became moribund were terminated. All animal experiments
were approved by the Massachusetts General Hospital
Animal Care Committee and guidelines for the care and
use of animals approved by the Institution were followed.
Photosensitiser
The photosensitiser used was a chlorin derivative, chlorin e6
monoethylendiamine monamide (CMA). CMA was obtained
from Porphyrin Products (Logan, UT, USA). The mono-
clonal antibody OC125 was a gift from Centocor (Malvern,
PA, USA). The immunoconjugate was synthesised by a
reaction at the carbohydrate moiety as previously described
(Goff et al., 1991). Briefly, polyglutamic acid (PGA) (Sigma,
St Louis, MO, USA) is bound to the CMA. The PGA-CMA
is then covalently linked to the carbohydrate moiety at the
hinge region of the monoclonal antibody away from the
antigen-binding sites.
Photoxicology studies
Mice were injected with 30 million NIH:OVCAR 3 cells.
Seven days after injection, animals were given an intraper-
itoneal injection of the immunoconjugate (0.5-4.0 mg kg-1).
Animals were immobilised and externally irradiated with an
argon-ion pumped-dye laser (Coherent Inc., Palo Alto, CA,
USA) at a wavelength of 656 nm (Lmax CMA). Exposure to
light was performed at 24 h based upon optimal tumour to
non-tumour ratios from biodistribution studies (Goff et al.,
1994). The power density was 40-70 mW cm-2 and the
fluence administered was 10-75 J cm-2. External irradiation
was easily employed for these initial studies because there was
no violation of the peritoneal cavity. Also in nude mice, the
abdominal wall is thin (<2 mm) so that it presents a minimal
barrier to 656 nm irradiation.
Photodynamic treatment in vivo
Mice were injected with 30 million NIH:OVCAR 3 cells.
Seven days after injection, animals were given an intraper-
itoneal injection of immunoconjugate (0.5-2.0 mg kg-');
controls were injected with sterile PBS. Twenty-four h later
animals were sedated with sodium pentobarbital and
intraperitoneal irradiation with an argon-ion pumped-dye
laser (Coherent Inc., Palo Alto, CA, USA) was carried out
using a cylindrically diffusing tip fibre as described by
Tochner et al. (1985, 1986). Briefly, the abdominal cavity
was divided into four roughly equal quadrants. The
cylindrically diffusing optical fibre was inserted through a
16 gauge needle into the abdominal cavity to a depth of
approximately 1 cm. Each quadrant was irradiated at 656 nm
for 1 min with a fluence of 50 mW at the fibre tip. Animals
were treated every 48 h for three or four treatments. One
group of animals was followed to determine survival. This
group consisted of 18 controls, ten animals treated with three
courses of PDT, and 12 animals treated with four courses of
PDT. Survival curves were estimated with the Kaplan-Meier
method.
In the second group of animals a quantitative assessment
ofthe extent of ovarian cancer cell destruction was performed
ex vivo. One hour after the final irradiation the ascites was
harvested with a 15 gauge needle. RBCs were lysed with
0.83% ammonium chloride (Aldrich Chemical, Milwaukee,
WI, USA). Ovarian cancer cells were washed in sterile
Dulbecco's PBS (Gibco) and placed in 35 mm petri dishes at
a concentration of 150 000 cells per ml in RPMI-1640
medium (Gibco) containing 10% fetal bovine serum. Forty-
eight hours after plating, survival of treated and control ex
vivo cultures was determined by the 3-(4,5-dimethylthiazol-2-
yl)-2,5 diphenyl terazolium bromide (MTT) colorimetric
assay (Mosman, 1983). In each group there were three to
five animals and all MTT assays were done in triplicate.
Results
Results of phototoxicology experiments are shown in Table I.
The percentages represent animals that survived 48 h following
photodynamic treatment with various light and immunoconju-
gate doses. Increasing phototoxicity was observed with
increasing light exposure or drug dosage. The phototoxic
LD50 is derived from the product of fluence and the injected
photosensitiser dose in mg kg-'; for our murine model this is
approximately 40. Reciprocity of light and drug dose was
observed. Necropsy of the animals which died owing to
phototoxicity revealed mild hepatic congestion and inflamma-
tion but no significant damage to kidney, bowel, spleen or skin.
Clinically, these animals had increasing abdominal distention
then became hypothermic and appeared to develop shock, with
death occuring 12-48 h following treatment.
The measurement of viable ovarian cancer cells following
intraperitoneal treatments with the OC125 immunoconjugate
and intraperitoneal light are shown in Table II. Initially,
single therapy was attempted. However, doses which reduced
viable tumour cells to 16% of controls were associated with a
50% rate of treatment toxicity deaths. A lower dose which
produced no treatment-related deaths resulted in a reduction
in viable tumour cells of only 34% of controls. In the next set
of experiments the lower dose was used; however, it was
repeated every 48 h for a total of three treatments. With this
approach, there were no deaths secondary to treatment
toxicity, while viable tumour cells were reduced to about 5%
of controls.
Based upon these results, an immunoconjugate and light
dose of 0.5 mg kg-' and 5 J cm-2, respectively, were used to
Table I Phototoxicology: tumour-bearing mice surviving PDTa
Light dose Immunoconjugate dose
(Jcm-2) 4 mg kg-' 2 mg kg-> J mg kg-' 0.5 mg kg-]
75 0% 0% -
50 0% 20% 86%
25 0% 30% 70% -
10 50% 80% 93% 100%
5 - 93% 100% 100%
aAnimals were injected with 30 million NIH:OVCAR3 cells. Seven
days after injection, animals were given an intraperitoneal injection of
immunoconjugate followed by exposure of the abdomen to 656 nm
light 24 h later. Numbers represent percentage of animals which
survived 48 h after treatment. Each group contains 10- 15 mice.Photoimmunotherapy of ovarian cancer


























































survival following intraperitoneal photodynamic localisation in ovarian cancer patients (Chatal et al., 1989).
s. Kaplan-Meier survival curves are shown in Iodine-131-labelled OC125 has been studied in phase I trials
The median survival for the control animals (n= 18) to treat recurrent ovarian cancer (Muto et al., 1992).
days, and all controls died between 30 and 50 days. However, the efficacy of these immunoconjugates remains
nice treated with three treatments, 40% were alive to be established. In experimental models, for doses that are
lays and the median survival was 47.5 days. For curative or inhibit tumour progression, systemic toxicity from
ted with four treatments, 58% were alive after 50 bound toxins and radioisotopes remains a significant problem
median survival was 58.0 days. Evaluation with log- because most monoclonal antibodies lack sufficient specificity
t revealed significant survival advantage with to preclude damage to normal organs.
)neal PDT compared with controls (P= 0.0006). Although PDT can, in principle, be more selective than
Dn, there was a trend towards improved survival some other modalities for cancer treatment, sites such as the
vs three treatments (P=0.1). peritoneal cavity are complex physically and optically. It is
Isies of the animals from survival studies show that this complexity that may be responsible for toxicity problems
ontrol animals die with massive ascites and a large noted clinically (Sindelar et al., 1991; Delaney et al., 1993) in
lurden compared with 27% of the treated animals. the intraperitoneal PDT with PF. Selective destruction of
maining 73% of the treated animals, the cause of target tissue in such situations requires a higher preferential
)eared secondary to the tumour. However, ascites tumour localisation by the photosensitiser than afforded by
abdominal tumours were much less extensive. The PF. Even second generation photosensitisers, such as
mour persistence in the treated group was in the benzoporphyrin derivative monoacid, do not offer much
domen around the liver and stomach, probably improved selectivity for this disease (Molpus et al., 1996). In
diminished light delivery and penetration. the early clinical trials using intraperitoneal PDT with PF,
there was substantial third spacing of fluids (Delaney et al.,
1993). Most patients exhibited fluid sequestration greater
than would be expected in a normal post-operative course,
and all developed significant hypoalbuminaemia (Sindelar et
cancer is the fifth most frequently occurring fatal al., 1991). In addition, 59% of the patients treated with
the United States. The majority of patients present intraperitoneal PDT developed pleural effusions post-opera-
III disease, and even with aggressive cytoreductive tively, and 15% required thoracentesis or prolonged
ad chemotherapy, 5 year survival rates are only 15- intubation. In a recent study by Takita et al. (1994)
,ently, monoclonal antibody conjugates have been evaluating PDT with PF for malignant pleural mesothelio-
or both tumour localisation and treatment in ovarian mas, the authors noted that there were excessive fluid
dium-l11-labelled OC125 has been used for tumour requirements for the first 24 h following PDT, which also
suggests that substantial third spacing (capillary leaking)
occurs following PDT. These earlier studies may provide an
explanation as to why the mice in our study appeared to
suffer acute circulatory collapse following high doses of PDT.
Assay of viable ovarian cancer cells following intraper- Other authors have postulated that the acute lethality ofPDT
al treatments of OC125 immunoconjugate and lighta in animal models may be related to the release of endogenous
ulative No. of Viable Death due vasoactive mediators, such as prostaglandins, thromboxane
treatments cellsc to toxicity and histamine (Ferrario and Gomer, 1990).
-20J cm-2 (40) 1 16.5%+8.4% 50% Using monoclonal antibodies to deliver photosensitisers is
-1_5J cm-2 (2.5) 1 34.2%+18.0% 0% relatively recent. The approach has the potential for
-1SJ cm32 (75) 3 5.±%1.5% 0% minimising normal tissue toxicity caused by either antibody-
Ls bearing ascites were injected with immunoconjugate and bound toxic ligands or the non-specific localisation of free
injection animals were given intraperitoneal radiation with photosensitiser such as PF. To date, reports of in vivo
ight. bCumulative PDD is cumulative photodynamic applications of this approach have been limited. In a recent
luct of fluence and injected photosensitiser in mg kg-l. relevant report, Schmidt et al. (1992) prepared immunocon-
represent percentage ofcells which survived as determined jugates of MAbs recognising CA125 on human ovarian
Lssay as compared with untreated controls. In each group cancer cells. In addition to showing selective photocytotoxi-
3-5 animals, (±represents standard deviation). city to target cells in vitro, and in vivo in a tumour-bearing
nude rat model, they treated three patients with advanced
ovarian cancer by intraperitoneal administration of 1 mg
MAb-phthalocyanine conjugate in Ringer's solution. At
laparotomy (72 h after coniugate administration), after
removal of gross tumour, the peritoneum was irradiated
with 50 J cm-2 670 nm light and histological evidence of
tumour cell death was obtained. In this present study, we
evaluated the toxicity and response to PDT using an OC125
-, immunoconjugate in a murine ovarian cancer model which
:-' ---, has many similarities to the clinical course of human ovarian
..... cancer.
Seven days after tumour cell inoculation was the time
chosen for all phototoxicology and PDT experiments,
.treat°mUents because at this time the tumours have formed implants and
Ln- 12) produced ascites. Also, the gross pathology at 7 days seemed
...... to represent a patient with diffuse abdominal disease but not
°nt18°oI treatments so far gone that the tuinour rapidly overwhelms the animal.
(n=10) Phototoxicology studies revealed that, when treating the
0 20 40 60 80 entire peritoneal surface, toxicity is both light and
Days immunoconjugate dose dependent. Significant toxicity was
observed with either high light or immunoconjugate doses.
I Kaplan-Meier survival curves of control mice The ex vivo cell survival studies we report in this paper show
d with those treated with three and four treatments of that a single photodynamic treatment is ineffective in
mmunoconjugate and intraperitoneal 656nm light. eradicating all of the ovarian cancer cells; thus, death from
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progressive ovarian carcinoma is not prevented. Even at the
single dose which results in a 50% treatment-related
mortality, 16% of cancer cells are still viable. However,
with multiple small fractions of immunoconjugate and light,
treatment-related deaths are avoided and the percentage of
viable cells is reduced even further. In a previous study (Goff
et al., 1994) we have shown that in vivo PDT using
unconjugated CMA results in significantly less tumour
cytotoxicity compared with the IC. Also, treatment of IC
without light did not produce any cytotoxicity (Goff et al.,
1991). Our results, along with the earlier work of Tochner et
al., 1985, 1986), provides strong evidence that, for optimal
tumoricidal effect, PDT needs to be administered like
conventional radiation therapy with multiple fractionated
treatments. Our in vivo survival studies confirm a statistically
significant survival advantage in animals treated with
intraperitoneal PDT (P=0.0006) with a trend towards
improved survival in those treated with four vs three
treatments (P=0.01). While all animals eventually died of
disease, animals treated with intraperitoneal PDT still
exhibited a substantial reduction in the amount of ascites
compared with controls. Furthermore, in the treated animals
the primary site of failure was in the upper abdomen around
the liver, which in the mouse model is a difficult area for
optimal light delivery.
Subcutaneously implanted human ovarian cancers in
animal models can be completely eradicated with photo-
dynamic therapy (Peterson et al., 1992). The murine
malignant ascites model used for our experiments is far
more complex, but it also more closely resembles advanced
ovarian cancer in women. Not surprisingly, we were not able
to eradicate intraperitoneal tumour deposit completely in this
initial study. Undoubtedly, the practical challenges posed by
the intraperitoneal murine experiments, such as delivery of
light, interactions with viscera and fluid third-spacing, will
require refinements in technique.
In summary, our initial in vivo results using this murine
model, particularly the selective phototoxicity to human
ovarian cancer cells and improved survival after fractionated
PDT treatments are encouraging and warrant further studies.
However, the fact that even after four treatments, 5% of the
cancer cells appeared to be viable, at least in the acute
toxicity testing, suggests that significant optimisation of the
treatment is still necessary. The observation that, in treated
animals, the site of tumour persistence was predominantly in
the upper abdomen around the liver and stomach suggests
that adequate delivery of light was a problem. Clearly, more
quantitative light delivery and dosimetry are necessary to
reduce phototoxic death from generalised irradiation of the
peritoneal cavity. These issues are currently being addressed
(Lilge et al., 1994) using multiple fibres for delivery and
dosimetry. There is also ample room for the improvement of
tumour uptake of the OC125 immunoconjugate. CA125 is
expressed by many normal tissues and this antigen is shed
efficiently (Bast et al., 1981, 1983). The use of more specific
antibodies, such as to products of oncogenes, or antibody
cocktails should improve the efficacy of PDT. The multiple
application of murine antibodies would pose another
potential problem. However, chimeric antibodies may
further enhance uptake and reduce the formation of human
anti-murine antibodies, which can interfere with therapies
that would require multiple treatments (Muto et al., 1990).
Because of the limited tissue penetration (- 5 mm) of 656 nm
light (Star et al., 1992), the most useful application of
photoimmunotherapy clinically will be for the eradication of
small residual disease following cytoreductive surgery,
microscopic disease or diaphragmatic studding. This treat-
ment option may be especially promising in patients with
minimal disease at the time of second-look laparotomy, since
PDT has been shown to be phototoxic to human ovarian
cancer cells that are platinum resistant (Pass, 1993; Goff et
al., 1991).
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